


Preliminary Q3 Results 2007

17 October 2007



Graphics: Sales (in million Euro)

Total Sales




* Excluding currency effect

- Sales decline is leveling off
- 14 million Euro impact from higher raw material costs in Q3
- Q3 EBIT margin prepress approx. 7%
- Slower market introduction in inkjet
- Q3 recurring EBIT expected to be in range of 12 to 15 million Euro
- Sales and profitability in Q4 expected to be in line with Q4 2006

HealthCare: Sales (in million Euro)


Total Sales



- Sales decrease due to strength of Euro with effect on price erosion
- Decline in medical film, affected by high stock levels at dealers
- Negative currency and mix effects
- One-off effects for approx. 7 million Euro in Q3
- Recurring EBIT in Q3 expected to be in range of 5 to 8 million Euro
- Traditionally higher sales in Q4 and additional impact from cost savings expected to restore EBIT margins in Q4 to a level above 10%

Specialty Products: Sales (in million Euro)

Total Sales



* Excluding currency effect

- Strong sales increase
- Profitability affected by higher silver costs and negative mix effects
- Q3 recurring EBIT expected to be in range of 6 to 8 million Euro
- Specialty Products expected to be in line with 12-15% EBIT margins for full year 2007

Conclusion

Graphics

- Good sales and profitability in prepress, despite headwinds such as raw material costs and price increases
- Speed of inkjet roll-out overestimated, but strong belief in technology and market potential

HealthCare

- Imaging segment important cash generator but further alignment of costs to declining film market needed
- State of the art IT portfolio, but execution of strategy and cost savings to be improved

Specialty Products

- Strong potential as consolidator of the film market
- Profitability highly dependent on mix effects

Questions & Answers

